Sanofi v Amgen antibody case lands front of queue at UPC

06-06-2023

Muireann Bolger

Sanofi v Amgen antibody case lands front of queue at UPC

Monticello / Shutterstock

Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind new court's low revocation count | Nearly half a million opt-outs registered.

The Unified Patent Court (UPC) may be less than a week old but it is already set to be the latest stage for the long-running dispute between Sanofi and Amgen concerning antibody patents.

As confirmed by lawyers to WIPR, the German division of French drugmaker Sanofi filed a revocation action against the US pharma company before the court’s central division in Munich citing patent number EP 3 666 797.

It marks a new twist in the global litigation waged between the two companies over antibody patents that wound its way to the US Supreme Court last month.


Amgen, court, patent, Sanofi, opt-outs, revocation, Unified, pan-European, French, pharma, venue

LSIPR